Different targeted therapies against HER2 have been tested in NSCLC without co-occurring EGFR mutations, including lapatinib, neratinib (HER2 and EGFR inhibitors) [36,37,103], and trastuzumab-deruxtecan (T-DXd, an ADC against HER2, linked to a topoisomerase I inhibitor). Here, EGFR is linked to non-small cell lung carcinoma.